MedTrace Logo

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

NCT05130073 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2024-02-20

No results posted yet for this study

Summary

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

Conditions

  • Anal Squamous Cell Carcinoma
  • Stage 0 Anal Cancer AJCC v8
  • Stage I Anal Cancer AJCC v8
  • Stage II Anal Cancer AJCC v8
  • Stage IIA Anal Cancer AJCC v8
  • Stage IIB Anal Cancer AJCC v8
  • Stage III Anal Cancer AJCC v8
  • Stage IIIA Anal Cancer AJCC v8
  • Stage IIIB Anal Cancer AJCC v8
  • Stage IIIC Anal Cancer AJCC v8

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Electronic Health Record Review

Review of medical records

PROCEDURE

Follow-Up

Undergo follow-up

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Benny Johnson · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2023-12-14
Completion
2023-12-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05130073 on ClinicalTrials.gov